Abstract

: The Oswaldo Cruz Foundation (FIOCRUZ) Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials), is a multidisciplinary, integrated research center based in Rio de Janeiro, Brazil that is partnered with the Institute de Pesquisa Clinica Evandro Chagas Clinical Research Site (IPEC CRS), Together the FioTrials CTU and IPEC CRS provide care for both at-risk and HIV infected persons and cater to the needs of certain disenfranchised populations, including men who have sex with men (MSM), transgender women, racial minorities, women, and those who are poverty stricken and/or uneducated. The FioTrials CTU and IPEC CRS have unique strengths to offer the AIDS Clinical Trials Group (ACTG), HIV Prevention Trials Network (HPTN) and Microbicide Trials Network (MTN), including a cadre of leading researchers; a partnership with FIOCRUZ, an internationally-recognized governmental organization dedicated to public health research; and a participant population that compliments the scientific agendas of each network. The goal of our research is to 1) evaluate and implement integrated strategies (therapeutic and behavioral) to prevent HIV acquisition in MSM, transgender women and women; 2) evaluate the safety, efficacy and utility of rectal microbicides for our MSM population; 3) evaluate novel diagnostics, technologies, prevention and treatment interventions for tuberculosis in HIV co-infected individuals; 4) evaluate novel treatment strategies for hepatitis C, particularly for those with HI co-infection; and 5) assess novel therapeutics and improve existing HIV treatment strategies and prevent co-morbidities. Achievement of these objectives will be attributed to the outstanding infrastructure of the FioTrials CTU, its CRS and its community-focused research strategies.

Public Health Relevance

The FioTrials CTU will continue to make significant contributions to the fight against the HIV/AIDS and tuberculosis epidemics in Brazil and throughout Latin America, particularly for the population of MSM and transgender women who are the most heavily affected by the burden of HIV in Brazil.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069476-09
Application #
8995613
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Roby, Gregg A,
Project Start
2008-01-15
Project End
2020-11-30
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
9
Fiscal Year
2016
Total Cost
Indirect Cost

  Institution

Name
Fundacao Oswaldo Cruz
Department
Type
DUNS #
899294177
City
Rio de Janeiro
State
Country
Brazil
Zip Code
21040-360

  Publications

Palumbo, Philip J; Fogel, Jessica M; Hudelson, Sarah E et al. (2018) HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. J Acquir Immune Defic Syndr 77:484-491
Cespedes, Michelle S; Kang, Minhee; Kojic, Erna Milunka et al. (2018) Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1. Papillomavirus Res 6:15-21
Swindells, S; Gupta, A; Kim, S et al. (2018) Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003). Int J Tuberc Lung Dis 22:1016-1022
Castro, Rodolfo; Crathorne, Louise; Perazzo, Hugo et al. (2018) Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Med Res Methodol 18:53
Caro-Vega, Yanink; Belaunzarán-Zamudio, Pablo F; Crabtree-Ramírez, Brenda E et al. (2018) Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America. Open Forum Infect Dis 5:ofy004
Côrtes, Fernanda H; de Paula, Hury H S; Bello, Gonzalo et al. (2018) Plasmatic Levels of IL-18, IP-10, and Activated CD8+ T Cells Are Potential Biomarkers to Identify HIV-1 Elite Controllers With a True Functional Cure Profile. Front Immunol 9:1576
Luz, Paula M; Osher, Benjamin; Grinsztejn, Beatriz et al. (2018) The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. J Int AIDS Soc 21:e25096
Robertson, K; Oladeji, B; Jiang, H et al. (2018) HIV-1 and TB Co-infection in Multinational Resource Limited Settings: Increased neurological dysfunction. Clin Infect Dis :
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life among HIV-infected individuals failing first-line antiretroviral therapy in resource-limited settings. AIDS Care 30:954-962
Glidden, David V; Mulligan, Kathleen; McMahan, Vanessa et al. (2018) Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clin Infect Dis 67:411-419

Showing the most recent 10 out of 127 publications